Net sales of insulin medications of Novo Nordisk in Greater China 2022, by type
In 2022, the Danish pharmaceutical company Novo Nordisk reported a net sales of over 4.9 billion Danish kroner from its premix insulin in Greater China. Diabetes care drug is the key product of the firm, generating over 15.2 billion net sales in the region that year.